Compare IDEXX Laboratories, Inc. (IDXX) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Matson Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Matson Inc trades at $214.74 (market cap $6.11B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.6× Matson Inc's market cap, and Matson Inc pays a 0.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MATX | |
|---|---|---|
Market Cap | $46.22B | $6.11B |
Sector | Health | Technology |
52-Week High | $766.68 | $223.55 |
52-Week Low | $526.44 | $88.05 |
Enterprise Value | $47.12B | $6.71B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Matson (MATX) trades at $214.45, up 2.76% with strong earnings momentum after beating Q2 2026 EPS estimates of $3.79 with $4.27 actual. The stock shows bullish technical signals with support at $200 and resistance at $209. Fundamentally, the company maintains solid profitability with 13.41% net margin and 17.21% ROE, supported by raised full-year guidance after strong Q2 results.
MATX presents a compelling investment case with 27.3% upside to consensus price target of $265, supported by 66.7% analyst buy ratings. Key risks include exposure to Trans-Pacific trade volatility and competitive shipping markets, but resilient consumer demand and premium China service position the company for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
